Institut Gustave Roussy

11 articles about Institut Gustave Roussy

• Sofinnova Partners and Gustave Roussy forge strategic alliance to boost oncology startup acceleration in France

  12/13/2023

  Sofinnova Partners and Gustave Roussy announced the launch of a strategic collaboration as part of Sofinnova Biovelocita, the first pan-European investment strategy dedicated to the creation and acceleration of biotech startups.

• LinKinVax and Gustave Roussy Announced First Patient Dosed in Phase I/IIa Clinical Study on HPV.DCVax in HPV-positive Oropharyngeal Cancer

  9/18/2023

  LinKinVax, a clinical-stage biotechnology company focusing on innovative protein-based vaccines, and Gustave Roussy, the leading cancer centre in Europe ranked third Best Cancer Hospital in the world, announced the treatment at Gustave Roussy of the first patient in a Phase I/IIa clinical study with CD40HVac, a new therapeutic vaccine candidate for HPV-positive oropharyngeal cancer.

• Veracyte and Gustave Roussy Announce Collaboration to Help Biopharmaceutical Companies Accelerate Development of Novel Cancer Therapies

  9/6/2023

  Partnership will leverage Gustave Roussy’s tumor samples and Veracyte’s Biopharma Atlas multi-omic database and machine learning capabilities.

• SOPHiA GENETICS Expands Relationship with Gustave Roussy

  8/22/2023

  SOPHiA GENETICS, a cloud-native software company in the healthcare space and a leader in data-driven medicine, announced the expansion of its relationship with Gustave Roussy, the leading cancer center in Europe.

• Gustave Roussy and THERYQ: France welcomes the first FLASH radiotherapy machine to treat patients

  7/12/2023

  Gustave Roussy and THERYQ announce a strategic and structuring partnership to roll out and assess FLASH technology for radiotherapy.

• LinKinVax and Gustave Roussy Collaborate on a Phase I/IIa HPV.DCVax Clinical Trial for the Treatment of Patients with HPV-Positive Oropharyngeal Cancer

  1/19/2023

  LinKinVax and Gustave Roussy announced a collaboration to conduct a first-in-human Phase I/IIa clinical trial with CD40HVac, a new therapeutic vaccine candidate against head and neck cancer associated with human papillomavirus (HPV).

• Pediatric Cancer Researchers Receive $1.3 Million to Study Precise Treatment for Neuroblastoma

  11/16/2020

  Grant awarded to CHOP and Gustave Roussy to support phase 3 clinical trial developed by Children's Oncology Group and International Society of Paediatric Oncology Europe Neuroblastoma Group, representing first-ever collaboration between North American and European neuroblastoma consortia

• Gustave Roussy and Protagen AG Collaborate to Improve the Risk Profiling of Cancer Patients Undergoing Immunotherapy

  4/10/2018

  Protagen AG and Gustave Roussy have today announced the start of a collaboration to utilize Protagen’s SeroTag® technology to help identify biomarkers that predict and monitor immune-related adverse events (irAEs) in cancer patients treated with checkpoint inhibitors.

• Delcath Systems, Inc. Announces Agreement With Institut Gustave Roussy for Launch of Hepatic CHEMOSAT Delivery System in France

  3/15/2012

• Treatment Interruption Fails Test in Gastrointestinal Stromal Tumors (GIST) , Institut Gustave Roussy Study

  9/22/2010

• ExonHit Therapeutics Inc. and Institut Gustave Roussy Announce the Signing of a License Agreement for Novel Breast Cancer Diagnostic Assay

  5/27/2009